metformin has been researched along with Cholangiocarcinoma in 20 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand." | 7.96 | Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin. ( Sookaromdee, P; Wiwanitkit, V, 2020) |
| " Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents." | 7.85 | Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. ( Dai, H; Ling, S; Shan, Q; Song, P; Wei, X; Xie, H; Xu, X; Yang, F; Zheng, S; Zhou, L; Zhuo, J, 2017) |
| " The combination of gemcitabine and cisplatin is the standard chemotherapy regimen for cholangiocarcinoma, but its benefit is limited." | 7.83 | Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. ( Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ, 2016) |
| "The antidiabetic drug metformin exerts antineoplastic effects in many types of malignancies, however the effect of metformin on cholangiocarcinoma (CCA) still remains unclear." | 7.81 | Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. ( Cui, Y; Gao, X; He, R; Jiang, X; Kang, P; Li, D; Li, F; Ma, N; Wan, M; Wang, D; Wang, Y; Zhang, F; Zhao, R; Zhou, Q, 2015) |
| "Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus." | 6.52 | Benefits of Metformin Use for Cholangiocarcinoma. ( Chavengkun, W; Eksanti, T; Kaewpitoon, N; Kaewpitoon, SJ; Kompor, P; Kootanavanichpong, N; Kujapun, J; Loyd, RA; Matrakool, L; Norkaew, J; Padchasuwan, N; Panpimanmas, S; Phatisena, T; Pholsripradit, P; Ponphimai, S; Rujirakul, R; Tongtawee, T, 2015) |
| "Metformin is a potent antiproliferative and anti-metastatic agent against human CCA cells." | 5.46 | Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB. ( Cha'on, U; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Wongkham, C; Wongkham, S, 2017) |
| "Metformin treatment also led to marked decreases in cyclin D1 and cyclin-dependent kinase (Cdk) 4 protein levels and retinoblastoma protein phosphorylation." | 5.42 | Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies. ( Fujihara, S; Fujimori, T; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Mori, H; Morishita, A; Okano, K; Suzuki, Y; Yamashita, T, 2015) |
| "Metformin is an oral anti-hyperglycemic agent of the biguanide family, which is used first-line for type II diabetes with few side-effects." | 5.40 | Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. ( Dong, C; Fan, N; Feng, T; Ke, Q; Li, L; Li, Y; Li, Z; Ling, S; Wang, C; Wang, L; Xu, F, 2014) |
| "The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand." | 3.96 | Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin. ( Sookaromdee, P; Wiwanitkit, V, 2020) |
| " Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents." | 3.85 | Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. ( Dai, H; Ling, S; Shan, Q; Song, P; Wei, X; Xie, H; Xu, X; Yang, F; Zheng, S; Zhou, L; Zhuo, J, 2017) |
| " The combination of gemcitabine and cisplatin is the standard chemotherapy regimen for cholangiocarcinoma, but its benefit is limited." | 3.83 | Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. ( Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ, 2016) |
| "The antidiabetic drug metformin exerts antineoplastic effects in many types of malignancies, however the effect of metformin on cholangiocarcinoma (CCA) still remains unclear." | 3.81 | Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. ( Cui, Y; Gao, X; He, R; Jiang, X; Kang, P; Li, D; Li, F; Ma, N; Wan, M; Wang, D; Wang, Y; Zhang, F; Zhao, R; Zhou, Q, 2015) |
| "Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus." | 2.52 | Benefits of Metformin Use for Cholangiocarcinoma. ( Chavengkun, W; Eksanti, T; Kaewpitoon, N; Kaewpitoon, SJ; Kompor, P; Kootanavanichpong, N; Kujapun, J; Loyd, RA; Matrakool, L; Norkaew, J; Padchasuwan, N; Panpimanmas, S; Phatisena, T; Pholsripradit, P; Ponphimai, S; Rujirakul, R; Tongtawee, T, 2015) |
| "Metformin is a potent antiproliferative and anti-metastatic agent against human CCA cells." | 1.46 | Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB. ( Cha'on, U; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Wongkham, C; Wongkham, S, 2017) |
| "Metformin treatment also led to marked decreases in cyclin D1 and cyclin-dependent kinase (Cdk) 4 protein levels and retinoblastoma protein phosphorylation." | 1.42 | Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies. ( Fujihara, S; Fujimori, T; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Mori, H; Morishita, A; Okano, K; Suzuki, Y; Yamashita, T, 2015) |
| "Metformin is an oral anti-hyperglycemic agent of the biguanide family, which is used first-line for type II diabetes with few side-effects." | 1.40 | Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. ( Dong, C; Fan, N; Feng, T; Ke, Q; Li, L; Li, Y; Li, Z; Ling, S; Wang, C; Wang, L; Xu, F, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 6 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laffusa, A | 1 |
| Ciaccio, A | 1 |
| Elvevi, A | 1 |
| Gallo, C | 1 |
| Ratti, L | 1 |
| Invernizzi, P | 1 |
| Massironi, S | 1 |
| Saengboonmee, C | 2 |
| Seubwai, W | 2 |
| Lert-Itthiporn, W | 1 |
| Sanlung, T | 1 |
| Wongkham, S | 2 |
| Sookaromdee, P | 1 |
| Wiwanitkit, V | 1 |
| Raggi, C | 1 |
| Taddei, ML | 1 |
| Sacco, E | 1 |
| Navari, N | 1 |
| Correnti, M | 1 |
| Piombanti, B | 1 |
| Pastore, M | 1 |
| Campani, C | 1 |
| Pranzini, E | 1 |
| Iorio, J | 1 |
| Lori, G | 1 |
| Lottini, T | 1 |
| Peano, C | 1 |
| Cibella, J | 1 |
| Lewinska, M | 1 |
| Andersen, JB | 1 |
| di Tommaso, L | 1 |
| Viganò, L | 1 |
| Di Maira, G | 1 |
| Madiai, S | 1 |
| Ramazzotti, M | 1 |
| Orlandi, I | 1 |
| Arcangeli, A | 1 |
| Chiarugi, P | 1 |
| Marra, F | 1 |
| Di Matteo, S | 1 |
| Nevi, L | 1 |
| Overi, D | 1 |
| Landolina, N | 1 |
| Faccioli, J | 1 |
| Giulitti, F | 1 |
| Napoletano, C | 1 |
| Oddi, A | 1 |
| Marziani, AM | 1 |
| Costantini, D | 1 |
| De Rose, AM | 1 |
| Melandro, F | 1 |
| Bragazzi, MC | 1 |
| Grazi, GL | 1 |
| Berloco, PB | 1 |
| Giuliante, F | 1 |
| Donato, G | 1 |
| Moretta, L | 1 |
| Carpino, G | 1 |
| Cardinale, V | 1 |
| Gaudio, E | 1 |
| Alvaro, D | 1 |
| Casadei-Gardini, A | 1 |
| Filippi, R | 1 |
| Rimini, M | 1 |
| Rapposelli, IG | 1 |
| Fornaro, L | 1 |
| Silvestris, N | 1 |
| Aldrighetti, L | 1 |
| Aimar, G | 1 |
| Rovesti, G | 1 |
| Bartolini, G | 1 |
| Vivaldi, C | 1 |
| Brunetti, O | 1 |
| Sperti, E | 1 |
| La Face, R | 1 |
| Ratti, F | 1 |
| Andrikou, K | 1 |
| Valgiusti, M | 1 |
| Bernardini, L | 1 |
| Argentiero, A | 1 |
| Fenocchio, E | 1 |
| Frassineti, GL | 1 |
| Cesario, S | 1 |
| Giovannelli, F | 1 |
| Quarà, V | 1 |
| Leone, F | 1 |
| Cascinu, S | 1 |
| Tang, D | 1 |
| Xu, L | 1 |
| Zhang, M | 1 |
| Dorfman, RG | 1 |
| Pan, Y | 1 |
| Zhou, Q | 2 |
| Zhou, L | 2 |
| Wang, Y | 2 |
| Li, Y | 2 |
| Yin, Y | 1 |
| Wang, L | 2 |
| Zou, X | 1 |
| Wandee, J | 2 |
| Prawan, A | 2 |
| Senggunprai, L | 2 |
| Kongpetch, S | 2 |
| Tusskorn, O | 1 |
| Kukongviriyapan, V | 2 |
| Chaiteerakij, R | 3 |
| Harmsen, WS | 2 |
| Ryu, E | 1 |
| Roberts, RO | 3 |
| Olson, JE | 2 |
| Therneau, TM | 2 |
| Roberts, LR | 3 |
| Fujita, T | 1 |
| Ling, S | 2 |
| Feng, T | 1 |
| Ke, Q | 1 |
| Fan, N | 1 |
| Li, L | 1 |
| Li, Z | 1 |
| Dong, C | 1 |
| Wang, C | 1 |
| Xu, F | 1 |
| Jiang, X | 1 |
| Ma, N | 1 |
| Wang, D | 1 |
| Li, F | 1 |
| He, R | 1 |
| Li, D | 1 |
| Zhao, R | 1 |
| Zhang, F | 1 |
| Wan, M | 1 |
| Kang, P | 1 |
| Gao, X | 1 |
| Cui, Y | 1 |
| Yang, Z | 1 |
| Zhang, X | 1 |
| Fujimori, T | 1 |
| Kato, K | 1 |
| Fujihara, S | 1 |
| Iwama, H | 1 |
| Yamashita, T | 1 |
| Kobayashi, K | 1 |
| Kamada, H | 1 |
| Morishita, A | 1 |
| Kobara, H | 1 |
| Mori, H | 1 |
| Okano, K | 1 |
| Suzuki, Y | 1 |
| Masaki, T | 1 |
| Kaewpitoon, SJ | 1 |
| Loyd, RA | 1 |
| Rujirakul, R | 1 |
| Panpimanmas, S | 1 |
| Matrakool, L | 1 |
| Tongtawee, T | 1 |
| Kootanavanichpong, N | 1 |
| Kompor, P | 1 |
| Chavengkun, W | 1 |
| Kujapun, J | 1 |
| Norkaew, J | 1 |
| Ponphimai, S | 1 |
| Padchasuwan, N | 1 |
| Pholsripradit, P | 1 |
| Eksanti, T | 1 |
| Phatisena, T | 1 |
| Kaewpitoon, N | 1 |
| Zhu, HQ | 1 |
| Ma, JB | 1 |
| Song, X | 1 |
| Gao, HJ | 1 |
| Ma, CQ | 1 |
| Chang, H | 1 |
| Li, HG | 1 |
| Liu, FF | 1 |
| Lu, J | 1 |
| Zhou, X | 1 |
| Cha'on, U | 1 |
| Sawanyawisuth, K | 1 |
| Wongkham, C | 1 |
| Xie, H | 1 |
| Yang, F | 1 |
| Shan, Q | 1 |
| Dai, H | 1 |
| Zhuo, J | 1 |
| Wei, X | 1 |
| Song, P | 1 |
| Xu, X | 1 |
| Zheng, S | 1 |
| Yang, JD | 1 |
| Slettedahl, SW | 1 |
| Mettler, TA | 1 |
| Fredericksen, ZS | 1 |
| Kim, WR | 1 |
| Gores, GJ | 1 |
3 reviews available for metformin and Cholangiocarcinoma
| Article | Year |
|---|---|
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diabetes Mellitus; Diabetes Melli | 2023 |
Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication.
Topics: Blood Glucose; Case-Control Studies; Cholangiocarcinoma; Diabetes Mellitus; Dipeptidyl-Peptidase IV | 2021 |
Benefits of Metformin Use for Cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Humans; Hypoglycemic Age | 2015 |
17 other studies available for metformin and Cholangiocarcinoma
| Article | Year |
|---|---|
Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin.
Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Diabetes Mellitus, Type 2; Endemic Diseas | 2020 |
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Electron Transpo | 2021 |
Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Cholangioc | 2021 |
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.
Topics: Bile Duct Neoplasms; Cholangiocarcinoma; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Mal | 2021 |
Metformin facilitates BG45‑induced apoptosis via an anti‑Warburg effect in cholangiocarcinoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Enzyme Inhibitors; Gen | 2018 |
Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Cycle; Ce | 2018 |
Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Cisplat | 2019 |
Reply: To PMID 23055147.
Topics: Cholangiocarcinoma; Diabetes Mellitus; Female; Humans; Liver Neoplasms; Male; Metformin | 2013 |
Analyzing risk factors for intrahepatic cholangiocarcinoma.
Topics: Cholangiocarcinoma; Diabetes Mellitus; Female; Humans; Liver Neoplasms; Male; Metformin | 2013 |
Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Topics: AMP-Activated Protein Kinase Kinases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumo | 2014 |
Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2015 |
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Diabetes Complications; Diabetes Mellitus; Female; Hu | 2016 |
Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Topics: Animals; Cell Proliferation; Cholangiocarcinoma; Diabetes Mellitus, Type 2; Gene Expression Regulati | 2015 |
Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Line, | 2016 |
Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
Topics: AMP-Activated Protein Kinases; Anoikis; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor | 2017 |
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Topics: AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Arsenicals; Bile Duct Neoplasms; Cell Line | 2017 |
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Case-Control Studies; | 2013 |